PL2392587T3 - Sekwencje i kompozycje peptydów - Google Patents

Sekwencje i kompozycje peptydów

Info

Publication number
PL2392587T3
PL2392587T3 PL11167363T PL11167363T PL2392587T3 PL 2392587 T3 PL2392587 T3 PL 2392587T3 PL 11167363 T PL11167363 T PL 11167363T PL 11167363 T PL11167363 T PL 11167363T PL 2392587 T3 PL2392587 T3 PL 2392587T3
Authority
PL
Poland
Prior art keywords
compositions
peptide sequences
peptide
sequences
Prior art date
Application number
PL11167363T
Other languages
English (en)
Inventor
Gregory Alan Stoloff
Wilson Romero Caparrós-Wanderley
Original Assignee
Peptcell Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0604920A external-priority patent/GB0604920D0/en
Priority claimed from GB0614260A external-priority patent/GB0614260D0/en
Application filed by Peptcell Ltd filed Critical Peptcell Ltd
Publication of PL2392587T3 publication Critical patent/PL2392587T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus
    • C07K14/155—Lentiviridae, e.g. human immunodeficiency virus [HIV], visna-maedi virus or equine infectious anaemia virus
    • C07K14/16—HIV-1 ; HIV-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55544—Bacterial toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16071—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • AIDS & HIV (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
PL11167363T 2006-03-10 2007-03-09 Sekwencje i kompozycje peptydów PL2392587T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0604920A GB0604920D0 (en) 2006-03-10 2006-03-10 Peptide sequences and compositions
GB0614260A GB0614260D0 (en) 2006-07-18 2006-07-18 Peptide sequences and compositions
EP07705325.4A EP2004676B1 (en) 2006-03-10 2007-03-09 Peptides of regulatory or accessory proteins of hiv, compositions and the utilization thereof
EP11167363.8A EP2392587B1 (en) 2006-03-10 2007-03-09 Peptide sequences and compositions

Publications (1)

Publication Number Publication Date
PL2392587T3 true PL2392587T3 (pl) 2016-08-31

Family

ID=38232608

Family Applications (1)

Application Number Title Priority Date Filing Date
PL11167363T PL2392587T3 (pl) 2006-03-10 2007-03-09 Sekwencje i kompozycje peptydów

Country Status (20)

Country Link
US (4) US20100055119A1 (pl)
EP (2) EP2392587B1 (pl)
JP (3) JP2009529570A (pl)
KR (1) KR20080106467A (pl)
CN (2) CN102443052B (pl)
AP (2) AP3642A (pl)
AU (1) AU2007226430B2 (pl)
BR (1) BRPI0708708A2 (pl)
CA (1) CA2645342A1 (pl)
DK (2) DK2004676T3 (pl)
EA (1) EA019733B1 (pl)
ES (2) ES2616341T3 (pl)
IL (2) IL193965A0 (pl)
MX (1) MX2008011520A (pl)
NO (1) NO20083576L (pl)
NZ (1) NZ570708A (pl)
PL (1) PL2392587T3 (pl)
SG (1) SG170092A1 (pl)
UA (1) UA97800C2 (pl)
WO (1) WO2007104932A2 (pl)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2620446A1 (en) 2012-01-27 2013-07-31 Laboratorios Del Dr. Esteve, S.A. Immunogens for HIV vaccination
CA2932788A1 (en) 2013-12-08 2015-06-11 Peptcell Limited Hiv antigens and antibodies and compositions, methods and uses thereof
KR20220011685A (ko) 2019-05-22 2022-01-28 길리애드 사이언시즈, 인코포레이티드 Tlr7 조절 화합물과 hiv 백신의 조합
EP4058058A1 (en) 2019-11-14 2022-09-21 Aelix Therapeutics S.L. Dosage regimens for vaccines

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0330359A3 (en) 1988-02-25 1991-06-05 Bio-Rad Laboratories, Inc. Composition useful in the diagnosis and treating of hiv-1 infection
DE4141970C2 (de) 1991-12-16 1998-02-19 Charite Med Fakultaet Kombinationsimpfstoff gegen AIDS, Bilharziose und Tuberkulose und Verfahren zu seiner Herstellung
CZ287239B6 (en) 1993-10-14 2000-10-11 Seikagaku Kogyo Co Ltd Polypeptides exhibiting antimicrobial and antiviral activity and pharmaceutical preparations containing thereof
AU685521B2 (en) 1993-10-19 1998-01-22 Ajinomoto Co., Inc. Peptide capable of inducing immune response against HIV and aids preventive or remedy containing the peptide
US5843724A (en) * 1995-04-27 1998-12-01 Rutgers University Chimeric nucleic acids and proteins for inhibiting HIV-1 expression
AU7689798A (en) * 1997-05-20 1998-12-11 St. Luke's-Roosevelt Hospital Vif-derived hiv protease inhibitors
PT2044950E (pt) 1997-09-18 2012-09-18 Univ Pennsylvania Cassetes de imunização adn de vif atenuadas para vacinas genéticas
US6228128B1 (en) 1997-11-10 2001-05-08 Charlotte Johansen Antimicrobial activity of laccases
US20020182222A1 (en) * 1998-07-10 2002-12-05 Groot Anne De HIV vaccine candidate peptides
US20030180314A1 (en) 1998-07-10 2003-09-25 Degroot Anne Immunogenic, cross-clade, HIV peptides
WO2000049038A2 (de) * 1999-02-19 2000-08-24 Ulrich Schubert Synthetische peptide des regulatorischen virusproteins r (vpr) des humanen immundefizienzvirus typ 1 (hiv-1) und ihre verwendung
NO311807B1 (no) 1999-03-04 2002-01-28 Bionor Immuno As HIV-peptider, antigener, vaksinepreparater, immunoassay- testsett og en metode for påvisning av antistoffer fremkalt av HIV
AU1075001A (en) * 1999-10-05 2001-05-10 Epimmune, Inc. Inducing cellular immune responses to human immunodeficiency virus-1 using peptide and nucleic acid compositions
CA2397998A1 (en) 2000-01-28 2001-08-02 Statens Serum Institut Hiv peptides and nucleic acids encoding them for diagnosis and control of hiv infection
NO314587B1 (no) 2000-09-04 2003-04-14 Bionor Immuno As HIV regulatoriske- og hjelpepeptider, antigener, vaksinepreparater, immunoassay testsett og en metode for påvisning av antistoffer fremkaltav HIV
EP1322338A4 (en) * 2000-10-04 2005-04-13 Univ Pennsylvania COMPOSITIONS AND METHODS OF USING A CAPSID PROTEIN FROM VARIOUS FLAVIVIRUS AND PESTIVIRUS
JP2004535369A (ja) * 2001-03-01 2004-11-25 アメリカ合衆国 試薬およびワクチンとして使用するための免疫原性ｈｉｖペプチド
RU2214274C2 (ru) 2001-08-16 2003-10-20 Государственное предприятие Институт иммунологии Федерального управления медико-биологических экстремальных проблем при МЗ РФ Иммуногенная композиция, содержащая химерный полипептид вич, полипептиды и тест-система для обнаружения антител к вич
US6974574B2 (en) * 2001-08-16 2005-12-13 The General Hospital Corporation Methods of inducing an HIV specific response using a Vpr-specific epitope
CA2357906A1 (en) 2001-09-28 2003-03-28 Institut Pasteur Identification of new cd8 epitopes from hiv-1 proteins with therapeutical and vaccinal properties against hiv infections
WO2004031345A2 (en) 2002-05-20 2004-04-15 The General Hospital Corporation Cytotoxic t-cell epitopes of hiv-1 virus
US20060079453A1 (en) 2002-10-03 2006-04-13 John Sidney Hla binding peptides and their uses
WO2005012502A2 (en) * 2003-03-28 2005-02-10 Idm Pharma, Inc. Methods of identifying optimal variants of peptide epitopes
BRPI0414443A (pt) * 2003-09-17 2006-11-21 Univ Duke imunógenos consensuais/ancestrais
EP1778282B1 (en) * 2004-08-17 2016-03-30 Institut Gustave Roussy Mutated hiv nef for modulating immunity
AU2006283101B2 (en) 2005-08-23 2013-03-07 Beth Israel Deaconess Medical Center Polyvalent vaccine

Also Published As

Publication number Publication date
HK1171027A1 (en) 2013-03-15
CN104558126B (zh) 2020-02-14
US20100055119A1 (en) 2010-03-04
AP2008004609A0 (en) 2008-10-31
EP2392587B1 (en) 2016-05-04
US20130039937A1 (en) 2013-02-14
WO2007104932A3 (en) 2007-11-22
EA200870342A1 (ru) 2009-02-27
ES2573105T3 (es) 2016-06-06
US20150182618A1 (en) 2015-07-02
US9675686B2 (en) 2017-06-13
AP2015008680A0 (en) 2015-08-31
EA019733B1 (ru) 2014-05-30
EP2004676B1 (en) 2016-11-16
AU2007226430A2 (en) 2008-10-09
JP2015007069A (ja) 2015-01-15
DK2392587T3 (en) 2016-05-23
IL193965A0 (en) 2011-08-01
CN102443052A (zh) 2012-05-09
MX2008011520A (es) 2009-01-07
CN102443052B (zh) 2014-12-31
CN104558126A (zh) 2015-04-29
EP2392587A1 (en) 2011-12-07
KR20080106467A (ko) 2008-12-05
SG170092A1 (en) 2011-04-29
US10034933B2 (en) 2018-07-31
AP3642A (en) 2016-03-16
CA2645342A1 (en) 2007-09-20
NO20083576L (no) 2008-12-10
JP2009529570A (ja) 2009-08-20
US20170281750A1 (en) 2017-10-05
AU2007226430A1 (en) 2007-09-20
IL219544A0 (en) 2012-06-28
JP2013040172A (ja) 2013-02-28
ES2616341T3 (es) 2017-06-12
JP6422698B2 (ja) 2018-11-14
AU2007226430B2 (en) 2013-08-29
EP2004676A2 (en) 2008-12-24
DK2004676T3 (en) 2017-02-20
UA97800C2 (uk) 2012-03-26
US8992934B2 (en) 2015-03-31
NZ570708A (en) 2011-12-22
BRPI0708708A2 (pt) 2011-06-07
WO2007104932A2 (en) 2007-09-20

Similar Documents

Publication Publication Date Title
IL251867A0 (en) Peptide sequences and compounds
GB0717864D0 (en) Peptide sequences and compositions
IL187617A0 (en) Lkktet and/or lkktnt peptide compositions and methods
PT2178549T (pt) Péptido antimicrobiano e suas composições
EP2017283A4 (en) Peptides
EP1976864A4 (en) NEW PEPTIDE AND ITS USE
IL195525A0 (en) Replikin peptides and uses thereof
GB0622399D0 (en) Novel compositions and uses thereof
GB0617171D0 (en) Novel compositions and methods
GB0604187D0 (en) Peptide and uses thereof
EP2010141A4 (en) NUCLEOTIDE COMPOSITIONS HAVING HIGH DEPOSITS AND USES THEREOF
GB0618748D0 (en) Peptide
GB0622400D0 (en) Novel compositions and uses thereof
EP2091959A4 (en) IMPROVED PEPTIDE COMPOSITION
ZA200806753B (en) Peptide sequences and compositions
GB0604920D0 (en) Peptide sequences and compositions
GB0614260D0 (en) Peptide sequences and compositions
GB0605774D0 (en) Peptide
IL192800A0 (en) Fgf2-binding peptides and uses thereof
HK1143743A (en) Peptide sequences and compositions
PL378824A1 (pl) Peptyd i jego zastosowanie
PL2195338T3 (pl) Interferon alfa zmodyfikowany na końcu N
GB0612873D0 (en) Isolated peptides and uses thereof
GB0625230D0 (en) Compositions and methods
GB0607565D0 (en) Methods and compositions